260 related articles for article (PubMed ID: 3158265)
21. Plasma thrombomodulin and alpha 2-plasmin inhibitor-plasmin complex are elevated in active systemic lupus erythematosus.
Kawakami M; Kitani A; Hara M; Harigai M; Suzuki K; Kawaguchi Y; Ishii H; Kazama M; Kawagoe M; Nakamura H
J Rheumatol; 1992 Nov; 19(11):1704-9. PubMed ID: 1337109
[TBL] [Abstract][Full Text] [Related]
22. Elastase- and plasmin-mediated fibrinolysis in rheumatoid arthritis.
Carmassi F; De Negri F; Morale M; Puccetti R; Chung SI
Int J Tissue React; 1994; 16(2):89-93. PubMed ID: 7960505
[TBL] [Abstract][Full Text] [Related]
23. [Plasma levels of antithrombin III, thrombin-antithrombin III complex, alpha 2 plasmin inhibitor and plasmin alpha 2 plasmin inhibitor complex in normal and sick newborn infants].
Shiiki M; Ariyoshi N; Nakamura T; Shirahata A
Rinsho Ketsueki; 1991 Jul; 32(7):758-65. PubMed ID: 1833569
[TBL] [Abstract][Full Text] [Related]
24. Univariate tolerance regions for fibrinogen, antithrombin III, protein C, protein S, plasminogen and alpha 2-antiplasmin in children using the new Automated Coagulation Laboratory (ACL) method.
Nowak-Göttl U; Funk M; Mosch G; Wegerich B; Kornhuber B; Breddin HK
Klin Padiatr; 1994; 206(6):437-9. PubMed ID: 7529848
[TBL] [Abstract][Full Text] [Related]
25. Plasminogen, alpha(2)-antiplasmin and complexes of plasmin-alpha(2)-antiplasmin (PAP) in amniotic fluid and blood plasma of parturient women.
Uszynski M; Klyszejko A; Zekanowska E
Eur J Obstet Gynecol Reprod Biol; 2000 Dec; 93(2):167-71. PubMed ID: 11074138
[TBL] [Abstract][Full Text] [Related]
26. Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
Collatos C; Barton MH; Prasse KW; Moore JN
J Am Vet Med Assoc; 1995 Aug; 207(4):465-70. PubMed ID: 7591947
[TBL] [Abstract][Full Text] [Related]
27. Changes in antithrombin, antiplasmin, and plasminogen during and after cardiopulmonary bypass.
Wolk LA; Wilson RF; Burdick M; Selik N; Brown J; Starricco A; Mammen EF
Am Surg; 1985 Jun; 51(6):309-13. PubMed ID: 3873197
[TBL] [Abstract][Full Text] [Related]
28. [Antithrombin III and alpha 2-antiplasmin in blood of patients operated on for benign prostatic hyperplasia].
Zietek Z; Iwan-Zietek I; Kotschy M; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):75-6. PubMed ID: 8756735
[TBL] [Abstract][Full Text] [Related]
29. [Clinical relevance of determination of plasma ATIII and alpha 2 PI activities in patients with DIC--application of the molecular markers for the analysis of pathophysiology of DIC].
Okajima K
Rinsho Byori; 1994 Jan; 42(1):45-55. PubMed ID: 8107283
[TBL] [Abstract][Full Text] [Related]
30. [Relationship between antiplasmin capacity and concentration of alpha 2-plasmin inhibitor, alpha 2-macroglobulin, alpha 1-antitrypsin, antithrombin III or C1-inactivator in plasma of patients with transient ischemic attacks (author's transl)].
Matsuda T; Seki T; Miura R; Ogawara M; Yokouchi M; Yamanouchi H
Rinsho Byori; 1980 Mar; 28(3):261-4. PubMed ID: 6154815
[No Abstract] [Full Text] [Related]
31. The suitability of various plasmin preparations for the functional assay of alpha 2-antiplasmin in plasma.
Kluft C; Traas DW; Jie AF; Hoegee-de Nobel E
Thromb Haemost; 1982 Dec; 48(3):320-4. PubMed ID: 6219471
[TBL] [Abstract][Full Text] [Related]
32. The influence of L-asparaginase therapy on the fibrinolytic system.
Vellenga E; Kluft C; Mulder NH; Wijngaards G; Nieweg HO
Br J Haematol; 1984 Jun; 57(2):247-54. PubMed ID: 6203549
[TBL] [Abstract][Full Text] [Related]
33. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
34. Kinetics of the inhibition of plasmin in acidified human plasma.
Lijnen HR; Maes M; Castel M; Samama M; Collen D
Thromb Haemost; 1982 Dec; 48(3):257-9. PubMed ID: 6219470
[TBL] [Abstract][Full Text] [Related]
35. Coagulation-fibrinolytic and kinin-forming systems in toxemia of pregnancy.
Hayakawa M; Maki M
Gynecol Obstet Invest; 1988; 26(3):181-90. PubMed ID: 3240888
[TBL] [Abstract][Full Text] [Related]
36. Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance.
Rodzynek JJ; Urbain D; Leautaud P; Wettendorff P; Delcourt A
Gut; 1984 Oct; 25(10):1050-6. PubMed ID: 6479679
[TBL] [Abstract][Full Text] [Related]
37. Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin).
Du XH; Glas-Greenwalt P; Kant KS; Allen CM; Hayes S; Pollak VE
Clin Nephrol; 1985 Oct; 24(4):186-91. PubMed ID: 3933871
[TBL] [Abstract][Full Text] [Related]
38. Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer.
Kaibara M; Watanabe T; Ooka F; Liang SG; Aisaka K; Okinaga S
Clin Hemorheol Microcirc; 2001; 24(2):93-9. PubMed ID: 11381184
[TBL] [Abstract][Full Text] [Related]
39. [Diagnosis of increased thrombotic tendency with chromogenic substrates].
Vinazzer H
Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):135-41. PubMed ID: 6177594
[TBL] [Abstract][Full Text] [Related]
40. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo.
Levi M; Roem D; Kamp AM; de Boer JP; Hack CE; ten Cate JW
Thromb Haemost; 1993 Feb; 69(2):141-6. PubMed ID: 7681223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
